Full-Life Technologies

Based in China, Full-Life Technologies operates as a medical service provider mainly engaged in the development, production, and commercialization of radiopharmaceuticals. Founded in 2021 and based in Shanghai, China, Full-Life Technologies is a medical company engaged in the development of nuclear therapy. The company's co-founder, chairman, and chief executive officer, Lanny Sun, served as partner and chief investment officer at Gordian Ventures. The branches were set up in Belgium and Germany.

Full-Life Technologies is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. In September 2025, Full-Life Technologies raised USD 50 million in series C led by new investor Junson Capital, with participation new investors Lapam Capital, Plaisance Capital, and TruMed Investment Management. Returning investors Chengwei Capital, Gordian Ventures, HSG, Prosperity7, Summer Capital, individual and other unspecified investors also participated in the round.

The round was a part of a larger USD 77 million in series C and debt funding. In September 2025, Full-Life Technologies raised USD 27 million in venture debt funding from unspecified investors. The round was a part of a larger USD 77 million in series C and debt funding. The company's business includes the production of radioisotopes and the development of a biological research platform for radiopharmaceutical therapy.

Its radio technology platform contains the production and logistics of radiopharmaceutical drug products.  The company generates revenue by doing research, development, production, and commercialization of radiopharmaceuticals and other related products. The funding raised in September 2025 to advance development of its radiopharmaceutical pipeline worldwide and manufacturing capabilities in Belgium.